Updated:
HealthEdge Investment Partners
HealthEdge Investment Partners, founded by Phillip Dingle and Scott Myers, targets lower-middle-market healthcare companies and has closed over 70...
HealthEdge Investment Partners
HealthEdge Investment Partners was formed in 2005 by Managing Partners Phillip S. Dingle and R. Scott Myers, both career healthcare operators and investors who previously held senior leadership roles at several medical technology companies. The firm operates from a single office in Tampa, Florida, targeting what it terms the 'sweet spot' of healthcare — founder-owned or family-run companies with $10 million to $100 million in revenue that require both capital and operational expertise to scale. The firm pursues buyout, growth-equity, and recapitalization transactions within a deliberately narrow band of healthcare sub-sectors: medical devices, specialty pharmaceutical services, outsourced clinical services, and healthcare distribution. HealthEdge structures its investments through committed private equity funds and parallel co-investment vehicles, typically taking majority control positions in portfolio companies. The firm's investment committee has historically emphasized businesses with regulatory moats, recurring revenue streams, and reimbursement alignment with Medicare and commercial payors. HealthEdge raised its third fund in 2019, and its portfolio has included companies such as Biologic Therapies, Inc. (specialty pharmacy) and MedTech Distributors, LLC (medical supply chain). The firm's professionals bring operating backgrounds from companies including Johnson & Johnson and Cardinal Health, a differentiator in a market where many lower-middle-market healthcare funds are staffed primarily by former investment bankers. In September 2021, HealthEdge completed the sale of ABB Optical Group, a portfolio company in optical distribution, after a multi-year hold period. The firm's structural distinction is its operator-first model — unlike many healthcare PE firms that bolt operating partners onto a finance core, HealthEdge's partnership is composed of former healthcare executives who manage the diligence and portfolio-operations functions directly. This has allowed the firm to pursue complex carve-outs of corporate healthcare divisions and navigate the FDA regulatory landscape without relying entirely on external consultants.
General information
Firm type
Private Equity
Year founded
2005
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Tampa
Corporate office
Tampa, FL, United States
Principals
Phillip S. Dingle
Managing Partner
R. Scott Myers
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at HealthEdge Investment Partners?
Investment decisions are made by Managing Partners Phillip S. Dingle and R. Scott Myers, who co-founded the firm in 2005. Both partners came to private equity from operating careers in the healthcare sector rather than traditional investment banking. The firm's partnership structure integrates investment sourcing, diligence, and portfolio operations under a single leadership team.
What is HealthEdge's investment strategy?
HealthEdge pursues control-equity investments in lower-middle-market healthcare companies with revenue between $10 million and $100 million. The firm targets three primary sub-sectors: medical devices, specialty pharmaceutical services, and outsourced healthcare services. Transaction types include majority buyouts, growth-equity recapitalizations, and corporate carve-outs.
Does HealthEdge invest from a committed fund structure?
Yes, HealthEdge raises committed private equity funds from institutional limited partners alongside parallel co-investment vehicles for larger platform transactions. The firm's third fund was raised in 2019, reflecting a multi-decade presence in the healthcare private equity market since the firm's founding in 2005.
Which sectors does HealthEdge explicitly avoid?
HealthEdge does not invest in healthcare IT software platforms, early-stage biotech, or provider practices that are fully dependent on government reimbursement rates with no commercial diversification. The firm's investment committee also avoids single-payer-dependent businesses and pure-play pharmaceutical drug development, preferring companies with diversified revenue streams across payors and product lines.
How is HealthEdge's team structured differently from other healthcare PE firms?
The firm's partnership is composed of former healthcare operators — including alumni of Johnson & Johnson and Cardinal Health — rather than career private equity professionals. This operator-first architecture means the diligence, investment committee decisions, and post-acquisition value-creation plans are led by individuals who have run healthcare businesses directly.
What is the geographic focus of HealthEdge's investments?
HealthEdge invests exclusively in US-based healthcare companies, with a concentration in the Southeast and Midwest where the firm's Tampa-based partnership has significant operational networks. While the firm does not pursue international platform investments, its portfolio companies often have global distribution channels in the medical device segment.
Does HealthEdge participate in fund commitments or only direct deals?
HealthEdge exclusively executes direct control-equity investments and does not operate as a fund-of-funds or make LP commitments to external managers. The firm's limited partners gain concentrated exposure to lower-middle-market healthcare operating businesses through a single-manager fund structure.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: